Tandem Meetings 2023 | Continuous IVIG and platelet transfusion for refractory AITP in patients undergoing alloSCT
Muhammad Umair Mushtaq
• 17 Feb 2023
Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, comments on the results of a study investigating the efficacy of continuous intravenous immunoglobulin (IVIG) and platelet transfusion in patients with refractory alloimmune thrombocytopenia (AITP) who are undergoing allogeneic stem cell transplantation (alloSCT). The study reported that this treatment led to a platelet response and bleeding resolution in all patients. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
